A 48 Week, Phase II, Open-Label, 2-Cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-Experienced Pediatric Subjects Aged 4 Weeks to greater than 2 Years.

Trial Profile

A 48 Week, Phase II, Open-Label, 2-Cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-Experienced Pediatric Subjects Aged 4 Weeks to greater than 2 Years.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Fosamprenavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2014 Planned End Date changed from 1 Jul 2015 to 1 Jun 2021 as reported by ClinicalTrials.gov.
    • 08 May 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top